Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure
- 1 September 2005
- journal article
- Published by Elsevier in American Heart Journal
- Vol. 150 (3) , 484-487
- https://doi.org/10.1016/j.ahj.2004.11.016
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunctionPublished by Oxford University Press (OUP) ,2004
- Circulating matrix metalloproteinase‐2 is elevated in patients with congestive heart failureEuropean Journal of Heart Failure, 2004
- N-terminal pro-brain natriuretic peptideA new gold standard in predicting mortality in patients with advanced heart failurePublished by Oxford University Press (OUP) ,2003
- Matrix Metalloproteinases and Tissue Inhibitors of MetalloproteinasesCirculation Research, 2003
- Two MMP-2 Promoter Polymorphisms (–790T/G and –735C/T) in Chronic Heart Failurecclm, 2003
- Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failureJournal of Cardiac Failure, 2002
- Matrix MetalloproteinasesCirculation Research, 2002
- Matrix Metalloproteinases in the Progression of Heart FailureDrugs, 2001
- Activation of Matrix Metalloproteinases in the Failing Human HeartCirculation, 1998
- Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosisThe American Journal of Cardiology, 1995